Related Experiment Video

Updated: Aug 12, 2026

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

34.1K

Targeted therapies and the treatment of non-clear cell renal cell carcinoma

J Bellmunt1, J Dutcher2

  • 1Solid Tumor Oncology (GU & GI), Medical Oncology Service, University Hospital del Mar-IMIM, Barcelona, Spain.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|April 30, 2013
PubMed
Abstract

Insights

Targeted therapies show promise for non-clear cell renal cell carcinoma (nccRCC). Current treatments approved for RCC are active in ncc subtypes, though further research is needed for optimal treatment strategies.

Area of Science:

  • Oncology
  • Nephrology
  • Medical Research

Background:

  • Advanced renal cell carcinoma (RCC) treatment has been revolutionized by targeted therapies.
  • Optimal treatment strategies for non-clear cell RCC (nccRCC) remain uncertain as these subtypes are often excluded from clinical trials.

Purpose of the Study:

  • To review and summarize current research on the biological characteristics, clinical behavior, and targeted therapy options for various nccRCC histological subtypes.
  • To assess the efficacy of existing RCC treatments in nccRCC patients.

Main Methods:

  • Extensive literature search of PubMed and ASCO databases.
  • Systematic review and summarization of research focusing on nccRCC and targeted therapy.

Main Results:

  • Approved RCC treatments demonstrate activity in nccRCC subtypes, but with potentially less clinical benefit compared to clear cell RCC.
  • Temsirolimus shows proven benefit over interferon-alfa (IFN-α) in nccRCC patients (Phase III data).
  • Everolimus, sunitinib, and sorafenib have shown some activity in nccRCC through expanded-access trials, but no specific subtype-treatment responsiveness is clear.

Conclusions:

  • Further molecular studies are essential to understand nccRCC pathogenesis and develop targeted agents.
  • Ongoing clinical trials are specifically evaluating targeted agents in nccRCC, with upcoming data from sunitinib and everolimus trials.
Keywords:
Xp11 translocated RCCchromophobe renal cell carcinomanon-clear cell RCCpapillary RCCsarcomatoid featurestargeted therapies

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.1K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.